121,302 Shares in KALA BIO, Inc. (NASDAQ:KALA) Purchased by AIGH Capital Management LLC

AIGH Capital Management LLC acquired a new stake in KALA BIO, Inc. (NASDAQ:KALA) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 121,302 shares of the company’s stock, valued at approximately $842,000. AIGH Capital Management LLC owned approximately 1.99% of KALA BIO at the end of the most recent quarter.

KALA BIO Trading Down 4.3 %

Shares of NASDAQ KALA opened at $6.05 on Friday. The company’s 50 day simple moving average is $7.70 and its 200 day simple moving average is $6.81. The firm has a market capitalization of $36.85 million, a P/E ratio of -0.49 and a beta of -2.19. KALA BIO, Inc. has a fifty-two week low of $4.21 and a fifty-two week high of $11.20. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.15 and a quick ratio of 2.15.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of KALA BIO in a research note on Thursday, February 13th.

Insider Transactions at KALA BIO

In other KALA BIO news, CEO Mark T. Iwicki sold 5,779 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.63, for a total value of $44,093.77. Following the transaction, the chief executive officer now owns 280,076 shares of the company’s stock, valued at approximately $2,136,979.88. This represents a 2.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Bros. Advisors Lp Baker purchased 310,559 shares of the stock in a transaction dated Monday, December 30th. The stock was bought at an average cost of $6.44 per share, with a total value of $1,999,999.96. Following the completion of the purchase, the insider now owns 1,083,398 shares in the company, valued at $6,977,083.12. The trade was a 40.18 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 9,506 shares of company stock worth $72,531 in the last three months. Insiders own 8.32% of the company’s stock.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.